Passive immunity in prevention and treatment of infectious diseases
about
A brief history of the antibiotic era: lessons learned and challenges for the futurePassive Immunization Against PoliomyelitisPost-exposure passive immunisation for preventing measlesPost-exposure passive immunisation for preventing measlesImmunogenetic mechanisms driving norovirus GII.4 antigenic variationConvalescent plasma: new evidence for an old therapeutic tool?Human monoclonal antibody-based therapy in the treatment of invasive candidiasisAnti-Pseudomonas aeruginosa IgY Antibodies Induce Specific Bacterial Aggregation and Internalization in Human Polymorphonuclear NeutrophilsUsing high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infectionWanted, dead or alive: New viral vaccinesMonoclonal antibody-based therapies for microbial diseasesAntigen-specific monoclonal antibodies isolated from B cells expressing constitutively active STAT5Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis modelUse of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role.Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID miceGeneration, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses.Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice.Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza.Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.Current Status of Dengue Therapeutics Research and Development.Production of recombinant antibodies using bacteriophages.Screening individual hybridomas by microengraving to discover monoclonal antibodies.Defining the humoral immune response to infectious agents using high-density protein microarrays.Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7.Botulinum neurotoxins and botulism: a novel therapeutic approach.Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein.Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model.Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.Prevention of maternal cytomegalovirus infection: current status and future prospects.Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting.Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.Can successful vaccines teach us how to induce efficient protective immune responses?The role of neutralizing antibodies for mouse mammary tumor virus transmission and mammary cancer development.High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient hostFunctional antibodies targeting IsaA of Staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseasesWorkshop on use of intravenous immunoglobulin in hand, foot and mouth disease in Southeast Asia.Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A.
P2860
Q21131155-0DC62F77-C8A9-4FAE-82A9-D8CAC5CB923BQ22305875-9A6231E1-F7D1-4073-9121-A2C449EEA0EFQ24197529-0088D50D-E23D-4A57-AAB0-04015ECD9B59Q24201001-E6B422F6-434B-448A-8DD4-634E70869222Q24810360-D96C756E-3B38-4249-9BBA-255F87F306A9Q26775412-31E9BE76-26F2-4B2A-8962-6A0FFB0F55DDQ26864291-A04017A0-D374-4B83-BB26-8EC7B24D487BQ27322540-3399211F-7E5D-4422-AE34-DA66C131BA90Q27488247-1CB98CE0-4A3C-49DA-953B-9537E24CEB99Q27489979-6A09A9F1-DD6C-4E9E-AFE7-F5F3BA6AB130Q27490830-2DDED956-3A30-46EA-B31F-799299679DD9Q28740998-B8E93E85-EE0D-4DEE-9ED9-D4EFEA3E0FCDQ28749838-9021FFFF-BEFC-4D23-94E4-3BE84844F679Q30145641-067310CA-21AA-4424-B88D-5458BAFE1790Q30342455-3684DF19-AC57-461C-9315-2C855E149982Q30353490-8F94E199-CF29-47A7-BBF3-1F25420D1685Q30361437-33E2968A-6C91-471E-8842-AD219A1C2E74Q30376814-40D9D1C8-0EEB-4E53-95AC-B414B3A0D24CQ30388253-42D7C795-2B47-453D-8F2D-F99ED12F313EQ30407946-85D70535-0EED-4604-9971-36F344233F99Q33210858-2BCF9ECB-6125-422C-9D68-581A44007AC3Q33552896-0ED7FFC3-5529-49FA-83CA-EB9D6A951BFAQ33643027-FFEFF83C-FCAE-48F8-9808-916EBA0CB04BQ33667656-8542E410-0EB3-4446-B226-97AB31A9EB9FQ33738002-414C7E1C-43ED-4A06-A809-0361A84581B7Q33965188-A30A3C2D-4F8E-4985-91FA-6604FB40B2EDQ34070659-7A059437-35FB-414E-8507-C75C27A73760Q34099149-8BF10B18-8399-4A0E-997F-BEC924DE2265Q34106926-B94FD52C-7F9B-462B-9E77-AB9A63F8CC34Q34230556-A73915B6-6736-4B6C-87F7-09E214104A8FQ34272089-A341A5D1-7810-4514-BB1B-79ABD58599B8Q34377438-AF4D1FE2-0BE0-4298-9AAD-5E93BF4461CDQ34407843-79CC3242-59C1-4FBC-81A2-E4AD0B5038A3Q34409182-32AA19C0-CB8C-4214-A66E-D676D15116E6Q34467281-253E6AD9-480E-4E26-9629-33B8E1738C11Q34472287-C72B8878-84C0-4969-AD51-BF5E5860198BQ34483544-469F966E-448A-4250-AF9E-F88F0C656ABBQ34536782-F5A81BC0-15BC-4454-9AE1-F5D4DD37C54FQ34844126-8E0016E8-6D5F-48EB-AAA7-D9515B2FE13EQ34944592-BE71DB4A-4973-4A04-B262-409FDA93B9A3
P2860
Passive immunity in prevention and treatment of infectious diseases
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Passive immunity in prevention and treatment of infectious diseases
@ast
Passive immunity in prevention and treatment of infectious diseases
@en
Passive immunity in prevention and treatment of infectious diseases
@nl
type
label
Passive immunity in prevention and treatment of infectious diseases
@ast
Passive immunity in prevention and treatment of infectious diseases
@en
Passive immunity in prevention and treatment of infectious diseases
@nl
prefLabel
Passive immunity in prevention and treatment of infectious diseases
@ast
Passive immunity in prevention and treatment of infectious diseases
@en
Passive immunity in prevention and treatment of infectious diseases
@nl
P2860
P921
P3181
P1476
Passive immunity in prevention and treatment of infectious diseases
@en
P2093
E R Stiehm
M A Keller
P2860
P304
P3181
P356
10.1128/CMR.13.4.602-614.2000
P407
P577
2000-10-01T00:00:00Z